Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Advocates claim Gilead and others unfairly limited competition for HIV combination pills.
Class action lawsuit challenges deals that limit generic drug competition; Gilead says the case is without merit.
But the presidential hopeful gets some criticism from a prominent AIDS activist: “Your plan is a great start but missed the bullseye.”
A look at June issues from the POZ archives
A photo journal of the #PrEP4All activists at the House hearings on Gilead, PrEP, and Truvada pricing.
Gilead Sciences CEO defends high drug prices and claims the CDC does not own the patent to HIV prevention pill Truvada.
Pharma giants made agreements to keep prices high and block competition for generics, the civil lawsuit alleges.
Only one company will sell a version of the HIV prevention pill Truvada. When others go to market, prices will likely drop further.
The “non-corporate, grassroots” march in NYC will be held the same day as the traditional Pride march.
Decades ago, Bill Bytsura photographed ACT UP members. Now he’s got a book.
If you don’t know why, then watch this 1992 video of ACT UP’s Ashes Action outside the White House.
Photographer and ACT UP member Bill Bytsura guides us through his decades-in-the-making book.
The 1988 “Seize Control of the FDA” AIDS protest forced major change and announced the arrival of ACT UP. Original activists discuss it.
Old school AIDS activism had everything to do with an electrifying moment during the Kavanaugh hearings.
U.S. activists unveil a national action plan to #BreakThePatent. It points out that taxpayers funded the research behind Truvada as PrEP.
Don’t miss these responses from seasoned activists and experts—including Peter Staley’s 31-point rebuttal in tweets.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.